Science & Delivery


AviadoBio has developed a next-generation AAV gene therapy platform focused on controlling gene expression and is complemented by a suite of unique delivery solutions to deliver gene therapies directly to the brain and spinal cord. We are also building additional platforms and capabilities as well as proprietary RNA silencing and subpial delivery technologies. Our neuroanatomy-led approach to viral vector distribution seeks to deliver our therapies to the right place to maximize their potential. 


AVB-101 is an investigational, adeno-associated virus (AAV) gene therapy for patients with frontotemporal dementia (FTD) with disease-causing mutations in the progranulin (GRN) gene. AVB-101 is designed as a one-time therapy to halt disease progression by delivering a functional copy of the GRN gene to restore progranulin levels throughout the brain. AVB-101 is designed to be administered intrathalamically to facilitate transport of the viral vector and the progranulin protein by exploiting the neuronal networks of the brain to  maximize biodistribution.

“What sets us apart is that we’re not just trying to do what’s easier but instead we’re challenging the status quo when it comes to next generation gene therapy development and delivery. At AviadoBio, we all take responsibility for our actions, and we know we can rely on our team members at all times to do what’s best for the company and patients.”

Alex Bloom, PhD

Chief Technology Officer

Aviadobio team A Bloom

Alex Bloom, PhD

Chief Technology Officer


Frontotemporal dementia (FTD) is a devastating form of early-onset dementia and is characterized by a rapid decline in executive function, behavior and/or language, and typically leads to death within seven to 13 years of symptom onset and three to 10 years from diagnosis.

find out more


Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig’s disease, is a devastating multisystem neurodegenerative disease. ALS is primarily characterized by degeneration of both upper and lower motor neurons.

find out more


Learn more about our mission to transform lives and our industry-leading team


Find out more about how we are progressing innovative gene therapies to potentially treat neurodegenerative disease. 


When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission



We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here